to-BBB raises €10m series-C

The company is also backed by Aescap Venture, family office Jonghoud International and the Industrial Bank of Taiwan.

Antea holds a stake of approximately 10% in to-BBB.

In conjunction with the funding round, the company has also announced the appointments of CFO Leonard Kruimer as interim CEO – replacing Willem van Weperen who is stepping down from his poisition – and Pericles Calias as senior vice president of translational medicine.

Previous funding
In August 2004, Antea provided early-stage capital to the company for a 9% stake, according to unquote" data. This was followed by a €4m capital injection from Aescap in July 2007.

Company
to-BBB was established in 2003 as a spinout from the blood-brain barrier research group of the Leiden and Amsterdam Centre for Drug Research at Leiden University.

The Leiden-headquartered company is developing treatments for brain diseases such as neuroinflammatory diseases and brain cancer. The biotech uses its G-Technology platform with existing drugs to enhance drug delivery across the blood-brain barrier.

It currently has two products in clinical trial. Its 2B3-101 product is designed for the treatment of primary brain tumours and metastatic brain cancer; it is currently in phase-IIa trials in Europe and the US. The company's 2B3-201 product is designed to treat multiple sclerosis relapses and other neuroinflammatory diseases; it is currently in phase-I clinical study.

People
Leonard Kruimer is CFO and interim CEO of to-BBB.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Netherlands